长春高新：子公司金赛药业一款针对晚期实体瘤的注射用药物获批临床

Core Viewpoint - Changchun High-tech announced that its subsidiary, Jinsai Pharmaceutical, received approval from the National Medical Products Administration for a clinical trial of GenSci139 in patients with advanced solid tumors, which may enhance the company's business scope and core competitiveness [1]. Group 1 - Jinsai Pharmaceutical has been granted a clinical trial approval for GenSci139, a dual-specific antibody-drug conjugate targeting EGFR and HER2 [1]. - GenSci139 is developed independently by Jinsai Pharmaceutical and possesses its own intellectual property rights [1]. - Successful progress in the clinical trial application could help the company expand its business range and optimize its product structure [1].